Company Filing History:
2 out of 5,094 
1 out of 2 
1 out of 280 
Years Active: 1991-2017
Title: Bernard Lebleu: Innovator in Apoptosis Inhibition and Antiviral Oligonucleotides
Introduction
Bernard Lebleu is a notable inventor based in Montpellier, France. He has made significant contributions to the fields of apoptosis inhibition and antiviral therapies. With a total of 2 patents, his work has implications for medical treatments and biological research.
Latest Patents
Lebleu's latest patents include innovative approaches to inhibiting apoptosis. One of his key inventions focuses on fragments of the Death-Domain Associated protein (DAXX) and the Fas-Associated Death Domain protein (FADD). These fragments are designed to inhibit cell apoptosis, particularly that mediated by the Fas receptor. The invention also encompasses derivatives, conjugates, and pharmaceutical compositions that utilize these fragments for treating diseases associated with apoptosis.
Another significant patent involves novel oligonucleotides with modified phosphate and carbohydrate structures. These oligonucleotides serve as mediators of interferon action and have antiviral applications. The specific formula of these oligonucleotides allows for diverse biological uses, showcasing Lebleu's innovative approach to addressing viral infections.
Career Highlights
Throughout his career, Bernard Lebleu has worked with esteemed institutions such as the Centre National de la Recherche Scientifique and Université Montpellier 2 - Sciences et Techniques. His research has contributed to advancements in both basic and applied sciences, particularly in the realm of molecular biology.
Collaborations
Lebleu has collaborated with notable colleagues, including Bernard Bayard and Stéphanie Barrere. These partnerships have fostered a collaborative environment that enhances research outcomes and innovation.
Conclusion
Bernard Lebleu's contributions to the fields of apoptosis inhibition and antiviral therapies highlight his role as a significant inventor. His patents reflect a commitment to advancing medical science and improving treatment options for various diseases.